What is the appropriate conversion dose from intravenous dexamethasone (Dexona) to oral prednisolone (Wysolone)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

IV Dexamethasone to Oral Prednisolone Conversion

Use a conversion ratio of 1 mg dexamethasone = 6.67 mg prednisolone (approximately 1:7 ratio) when transitioning from IV dexamethasone to oral prednisolone. 1, 2

Standard Conversion Calculation

  • The FDA-approved equivalency table indicates that 2.25 mg dexamethasone equals 15 mg prednisolone, yielding a 1:6.67 conversion ratio. 1
  • For practical dosing, round to a 1:7 ratio (1 mg dexamethasone = 7 mg prednisolone) for ease of calculation. 1
  • This conversion applies specifically to oral or intravenous administration; intramuscular or intra-articular routes may alter relative potencies. 1

Example Conversions:

  • 4 mg IV dexamethasone = approximately 28 mg oral prednisolone 1
  • 8 mg IV dexamethasone = approximately 56 mg oral prednisolone 1
  • 20 mg IV dexamethasone = approximately 140 mg oral prednisolone 1

Post-Pulse Transition Protocol

When transitioning from high-dose IV dexamethasone pulse therapy to oral prednisolone maintenance:

  • Start oral prednisolone at 0.5-1 mg/kg/day (maximum 60 mg/day) after completing IV pulse therapy, regardless of the exact dexamethasone dose used. 3, 4
  • Maintain the initial high dose for approximately 1 month before beginning tapering to ensure adequate disease control. 3
  • Do not reduce the oral dose below 15 mg/day during the first 3 months of treatment for conditions like vasculitis. 3, 4

Tapering Schedule

  • Begin tapering after the first month by reducing prednisolone by 5-10 mg weekly until reaching 20 mg daily. 3, 4
  • Below 20 mg daily, taper more slowly (1-2.5 mg decrements every 1-2 weeks) to minimize relapse risk. 3
  • Complete tapering typically occurs over 3-6 months depending on clinical response and disease severity. 3, 4

Pharmacokinetic Considerations

  • Dexamethasone has a significantly longer half-life (approximately 190 minutes) compared to prednisolone (approximately 100 minutes), which explains its more prolonged immunosuppressive effects. 2
  • Both medications demonstrate similar bioavailability when given orally (>80%), making oral prednisolone an appropriate maintenance option after IV dexamethasone. 5, 2
  • The receptor-binding affinity of dexamethasone is approximately 5-7 times higher than prednisolone, which correlates with the dose equivalency ratio. 2, 6

Common Pitfalls to Avoid

  • Do not use a 1:1 conversion ratio between dexamethasone and prednisolone, as this will result in significant underdosing. 1, 2
  • Avoid abrupt discontinuation after long-term therapy; always taper gradually to prevent adrenal insufficiency. 1
  • Do not assume methylprednisolone and prednisolone are equivalent; methylprednisolone is approximately 1.25 times more potent than prednisolone. 3, 1
  • Monitor for disease rebound during the first 2-4 weeks after transitioning from IV to oral therapy, as this is when relapse risk is highest. 3

Monitoring Requirements

  • Assess for signs of disease recurrence during tapering, particularly when reducing below 20 mg/day prednisolone. 3
  • Monitor for steroid-related adverse effects including hyperglycemia, hypertension, weight gain, and bone density loss. 3
  • Consider prophylaxis for Pneumocystis jiroveci pneumonia and gastric protection with proton pump inhibitors during prolonged high-dose therapy. 7, 8
  • Implement bone protection strategies (calcium 1000-1500 mg/day, vitamin D 800-1000 IU/day) if therapy is anticipated to exceed 3 months. 8

References

Guideline

Oral Steroid Regimen Following Pulse Methylprednisolone

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

IV Methylprednisolone Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Pulse Methylprednisolone Therapy Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.